Understanding Brain Reward Responses in Individuals With Major Depressive Disorder

NCT00183755 | Completed DMC

• 2 other identifiers: R01MH068376DATR A3-NSS
• Study Type: observational
• Target: 87
• Locations: 1 country
• Sites: 3

Brief Summary

This study will examine brain responses associated with reinforcement and reward tasks in individuals with major depressive disorder (MDD).

Conditions

Depression

Keywords

Reward Processing; Anhedonia; Major Depressive Disorder; Depression

Outcome Measures

Primary Outcomes (2)

• Performance on Monetary Incentive Delay task

  This task features balanced incentive delivery and analytic strategies designed to identify activity specific to anticipation or consumption of incentives.

  Given once during the second session for half an hour, and once during the third session for half an hour

• Signal detection reward task

  This reward task provides an objective assessment of hedonic capacity. Due to the probabilistic nature of the task, participants cannot infer which stimulus is more advantageous based on the outcome of single trials but need to integrate reinforcement history over time to optimize behavior.

  Given once during the second session for fifteen minutes, and once during the third session for fifteen minutes

Study Arms (2)

1

Control participants

2

Participants with MDD

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Control participants, Participants with MDD

You may qualify if:

• Right-handed
• Agrees to use an effective form of contraception throughout the study
• Meets DSM-IV diagnosis criteria for major depressive disorder
• Score of at least 16 on the 21-item HAM-D scale

You may not qualify if:

• Left-handed or ambidextrous
• Claustrophobic
• Neurological or medical illness (e.g., attention deficit hyperactivity disorder, head injury, loss of consciousness, seizures)
• Pregnant
• Has been treated with electroconvulsive therapy within 6 months of study entry
• Has taken any benzodiazepine medications for at least 2 weeks prior to study entry and discontinued use of the medication for reasons other than participating in the study
• Has taken any dopaminergic medications (including methylphenidate) or neuroleptics for at least 6 months prior to study entry and discontinued use of the medication for reasons other than participating in the study
• Has taken any fluoxetine medications for at least 6 weeks prior to study entry and discontinued use of the medication for reasons other than participating in the study
• Has taken any medications that may have antidepressant properties (including some herbal supplements) within 2 weeks of study entry
• Has taken any medications that may affect blood flow (including some blood pressure medications) within 2 weeks of study entry
• Current or past history of MDD with psychotic features
• Meets DSM-IV diagnosis criteria for organic mental disorder; substance use disorder (within 1 year of study entry); lifetime substance dependence; schizophrenia; delusional disorder; bipolar disorder; post-traumatic stress disorder; eating disorder; acute bereavement; severe borderline or antisocial personality disorder; or any psychotic disorder not otherwise specified
• Current primary diagnosis of panic disorder, social phobia, generalized anxiety disorder, obsessive-compulsive disorder, or somatoform disorder
• Diagnosed with any medical or neurological illness
• Diagnosed with any current or past psychiatric illness, as assessed by the SCID-I, including substance abuse or dependence (e.g., alcohol)

Sponsors & Collaborators

• Mclean Hospital: lead
• National Institute of Mental Health (NIMH): collaborator

Study Sites (3)

The Depression Clinical and Research Program, Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Affective Neuroscience Laboratory, Department of Psychology, Harvard University

Cambridge, Massachusetts, 02138, United States

Location

Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital

Charlestown, Massachusetts, 02129, United States

Location

Related Publications (1)

• Pizzagalli DA, Holmes AJ, Dillon DG, Goetz EL, Birk JL, Bogdan R, Dougherty DD, Iosifescu DV, Rauch SL, Fava M. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry. 2009 Jun;166(6):702-10. doi: 10.1176/appi.ajp.2008.08081201. Epub 2009 May 1.

  PMID: 19411368 DERIVED

MeSH Terms

Conditions

Depression; Anhedonia; Depressive Disorder, Major

Condition Hierarchy (Ancestors)

Behavioral Symptoms; Behavior; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Depressive Disorder; Mood Disorders; Mental Disorders

Study Officials

• Diego A. Pizzagalli, PhD

  Harvard University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor, Harvard Medical School

Study Record Dates

• First Submitted: September 14, 2005
• First Posted: September 16, 2005
• Study Start: April 1, 2005
• Primary Completion: April 1, 2009
• Study Completion: April 1, 2009
• Last Updated: April 21, 2014

Record last verified: 2014-04

Locations

US (3)